🔎 Trials Near Me

መነሻ › አውቶኢሙን ሕመሞች › ማሳቹሴትስ › Boston

በBoston፣ MA ለአውቶኢሙን ሕመሞች የሚደረጉ ክሊኒካዊ ጥናቶች

ለአውቶኢሙን ሕመሞች የሚደረጉ 13 ጥናቶች በBoston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Tufts Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07621809

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT03816345

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06722235

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
እድሜ ከ6 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06154252

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT06948318

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Boston Children's Hospital, Boston
  • እና 1 ተጨማሪ
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06121297

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Beth Israel Deaconess Medical Center, Boston
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ13 ኦገስ 2026 · NCT06359041

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Boston Children's Cancer Center, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06056297

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Brigham And Womens Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ጁላይ 2026 · NCT07115745

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess, Boston
  • Dana Farber Cancer Institute, Boston
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Tufts University, Boston
  • Massachusetts General Hospital, Boston
  • Brigham and Women's Hospital, Boston
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁን 2026 · NCT06201416

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Brigham and Women's Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሜይ 2026 · NCT04422912

Testimonials and Navigation in Rheumatology

ተሳታዮችን በመፈለግ ላይ
  • Brigham Women's Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ሜይ 2026 · NCT06469788

በሌሎች ከተሞች ለአውቶኢሙን ሕመሞች የሚደረጉ ጥናቶች

በBoston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።